Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Relmapirazin - MediBeacon

Next Previous
Drug Profile

Relmapirazin - MediBeacon

Alternative Names: APC2; Lumitrace; MB 102; MP-3180; PP 2338

Latest Information Update: 31 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mallinckrodt Inc.
  • Developer MediBeacon
  • Class Diagnostic agents; Pyrazines; Small molecules
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Kidney disorders
  • Phase III Acute kidney injury
  • No development reported Crohn's disease

Most Recent Events

  • 21 Oct 2025 Registered for Kidney disorders (Diagnosis) in China (IV)
  • 15 Apr 2024 MediBeacon completes a phase III trial in Acute kidney injury and Kidney disorders (Diagnosis) in USA (IV) (NCT05777174)
  • 30 Nov 2023 Hangzhou Zhongmei Huadong Pharmaceutical completes a phase III trial in Kidney disorders (Diagnosis) in China (IV) (NCT05943977)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top